1 Title

- 2 Epigenomic signature of major congenital heart defects in newborns with Down syndrome
- 3

4 Authors

- 5 Julia S. Mouat^{1,2,3,4}, Shaobo Li⁵, Swe Swe Myint⁵, Benjamin I. Laufer^{1,2,3,4}, Philip J. Lupo⁶,
- 6 Jeremy M. Schraw⁶, John P. Woodhouse⁶, Adam J. de Smith^{*5}, Janine M. LaSalle^{*1,2,3,4}
- 7 *Equal contributors
- 8 Corresponding author: Janine LaSalle, jmlasalle@ucdavis.edu
- 9

10 Affiliations

- ¹Department of Medical Microbiology and Immunology, School of Medicine, University of
- 12 California, Davis, CA USA
- 13 ²Perinatal Origins of Disparities Center, University of California, Davis, CA USA
- ¹⁴ ³Genome Center, University of California, Davis, CA USA
- 15 ⁴MIND Institute, University of California, Davis, CA USA
- ⁵ Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck
- 17 School of Medicine, University of Southern California, CA USA
- ⁶Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine,
- 19 Houston, TX USA
- 20
- 21
- 22
- 23
- **•** •
- 24
 - r
- 25
- 26

27 ABSTRACT

Background: Congenital heart defects (CHDs) affect approximately half of individuals with Down syndrome (DS) but the molecular reasons for incomplete penetrance are unknown. Previous studies have largely focused on identifying genetic risk factors associated with CHDs in individuals with DS, but comprehensive studies of the contribution of epigenetic marks are lacking. We aimed to identify and characterize DNA methylation differences from newborn dried blood spots (NDBS) of DS individuals with major CHDs compared to DS individuals without CHDs.

34

35 Methods: We used the Illumina EPIC array and whole-genome bisulfite sequencing (WGBS) to 36 quantitate DNA methylation for 86 NDBS samples from the California Biobank Program: 1) 45 37 DS-CHD (27 female, 18 male) and 2) 41 DS non-CHD (27 female, 14 male). We analyzed global 38 CpG methylation and identified differentially methylated regions (DMRs) in DS-CHD vs DS non-39 CHD comparisons (both sex-combined and sex-stratified) corrected for sex, age of blood 40 collection, and cell type proportions. CHD DMRs were analyzed for enrichment in CpG and genic 41 contexts, chromatin states, and histone modifications by genomic coordinates and for gene 42 ontology enrichment by gene mapping. DMRs were also tested in a replication dataset and 43 compared to methylation levels in DS vs typical development (TD) WGBS NDBS samples.

44

Results: We found global CpG hypomethylation in DS-CHD males compared to DS non-CHD males, which was attributable to elevated levels of nucleated red blood cells and not seen in females. At a regional level, we identified 58, 341, and 3,938 CHD-associated DMRs in the Sex Combined, Females Only, and Males Only groups, respectively, and used machine learning algorithms to select 19 Males Only loci that could distinguish CHD from non-CHD. DMRs in all comparisons were enriched for gene exons, CpG islands, and bivalent chromatin and mapped to genes enriched for terms related to cardiac and immune functions. Lastly, a greater percentage

of CHD-associated DMRs than background regions were differentially methylated in DS vs TD
 samples.

54

55 Conclusions: A sex-specific signature of DNA methylation was detected in NDBS of DS-CHD
 56 compared to DS non-CHD individuals. This supports the hypothesis that epigenetics can reflect
 57 the variability of phenotypes in DS, particularly CHDs.

58

59 Keywords

- 60 Down syndrome, congenital heart defect, newborn dried blood spot, DNA methylation, whole-
- 61 genome bisulfite sequencing, epigenetics, epigenome-wide association study, differentially
- 62 methylated regions, nRBC, hypomethylation
- 63

64 List of abbreviations:

- 65 DS: Down syndrome
- 66 CHD: Congenital heart defect
- 67 AVSD: Atrioventricular septal defect
- 68 WGBS: Whole-genome bisulfite sequencing
- 69 NDBS: Newborn dried blood spot
- 70 TD: Typical development
- 71 DMR: Differentially methylated region
- 72 QC: Quality control
- 73 nRBC: Nucleated red blood cell
- 74 PCA: Principal component analysis
- 75 EPO: Erythropoietin
- 76 TAM: Transient abnormal myelopoiesis

78 MANUSCRIPT

79

80 **1. Introduction**

81 Down syndrome (DS) is a set of distinct clinical features that result from trisomy 21, the most 82 common autosomal aneuploidy across live births. Clinical characteristics of DS vary across 83 individuals but include intellectual disability, short stature, muscle hypotonia, atlantoaxial 84 instability, reduced neuronal density, cerebellar hypoplasia, and congenital heart defects (CHDs) 85 (1). CHDs affect ~50% of newborns of both sexes with DS (2–5) despite their diagnosis in only 86 ~1% of newborns without DS (6). The most frequently diagnosed CHD in children with DS is an 87 atrioventricular septal defect (AVSD), a condition characterized by a large hole in the heart due 88 to improper development of the endocardial cushion. Many cases of DS-CHDs, particularly AVSD, 89 are diagnosed in utero by ultrasound, but others are not diagnosed until after birth following 90 obvious symptoms or an echocardiogram and often require surgery.

91

92 The mechanisms influencing the development of CHDs among individuals with DS are not clear. 93 Studies of partial trisomy 21 patients have pinpointed critical regions on chromosome 21, 94 including the Down syndrome cell adhesion molecule (DSCAM) gene, that appear to underlie 95 CHD development (7), but these have not addressed the incomplete penetrance among 96 individuals with complete trisomy 21. Additionally, genome-wide association studies and 97 candidate-gene approaches have identified variants on chromosomes throughout the genome 98 that are associated with CHDs in DS (8–13). However, these genetic variants do not sufficiently 99 explain CHD risk among those with DS.

100

101 Another molecular driver or biomarker of CHD risk in children with DS may be epigenetic 102 mechanisms such as DNA methylation. Increasing evidence has shown epigenetic alterations 103 and gene-environment interactions to be involved in the pathogenesis of non-syndromic CHDs

104 (14,15), but comprehensive studies of genome-wide DNA methylation variation associated with 105 DS-CHD are lacking. We previously used whole-genome bisulfite sequencing (WGBS) of 106 newborn dried blood spots (NDBS) to examine methylation profiles in 11 DS-CHD compared to 107 10 DS non-CHD samples, as part of a larger DS vs typical development (TD) study (16). There 108 were 1,588 nominally significant (p < 0.05) differentially methylated regions (DMRs) (35%) 109 hypermethylated, 65% hypomethylated) distinguishing DS-CHD from DS non-CHD and these 110 regions were enriched for terms related to the heart, as well as neurodevelopment and 111 metabolism (16). These promising but preliminary results suggesting an epigenomic signature of 112 CHD within DS led us to conduct the present study.

113

114 This current study used WGBS of NDBS obtained from the California Biobank Program among 115 86 DS individuals with and without major CHDs to identify specific loci, biological pathways, and 116 genic contexts that are associated with risk for CHDs in the DS population. Very few studies have 117 conducted WGBS on NDBS, a sample source that is accessible, widely banked, reflective of the 118 intrauterine period, and informative regarding dysregulation in other tissues, including the brain 119 and the heart (16). In contrast to reduced representation methods such as arrays, this WGBS 120 study provides insight to the entire DS-CHD epigenome, particularly because regional methylation 121 smoothing approaches increase confidence over regions with relatively low coverage. 122 Additionally, our study investigates similarities/differences in molecular signatures of DS-CHD in 123 males compared to females, as well as DS-CHD compared to DS (versus TD). Our findings 124 showed sex-specific global and region-specific changes to methylation that may serve as 125 biomarkers and/or be functionally important in the development of CHDs in individuals with DS.

126

127 **2.** Methods

128 **2.1 Study Populations and DNA extraction from NDBS**

129 This study was approved by Institutional Review Boards at the California Health and 130 Human Services Agency, University of Southern California, and University of California, 131 Davis. For the Discovery study, deidentified NDBS were obtained from 90 newborns with 132 DS from the California Biobank Program (CBP, SIS request number 572), with a waiver 133 of consent from the Committee for the Protection of Human Subjects of the State of 134 California (17). Demographic and birth-related data, including sex, race/ethnicity, 135 birthweight, gestational age, and age of blood collection were obtained from the CBP 136 (Supplemental Tables S1-S2). DS newborns with CHD or without CHD were identified 137 via linkage between the California Department of Public Health Genetic Disease 138 Screening Program and the California Birth Defects Monitoring Program (CBDMP). In 139 brief, the CBDMP is a population-based surveillance program that covers ~30% of the 140 births in California, including 10 counties, which are representative of the state's 141 population (18). Birth defects diagnosis data from CBDMP for the 90 newborns were 142 coded into "major birth defects" and "major heart defects" using guidelines from the 143 National Birth Defects Prevention Network (6). Major defects included AVSD and tetralogy 144 of Fallot. We identified 46/90 newborns with a CHD, of which 44 were AVSDs, and 3 had 145 tetralogy of Fallot. For this study, we focused on major heart defects and following sample 146 QC (described below) we included 45 DS with CHD (27 female, 18 male) and 41 DS 147 without CHD (27 female, 14 male). DNA was extracted from one 4.7 mm card punch of 148 each of the 90 NDBS, roughly 1.4cm in diameter, with the Beckman Coulter GenFind V3 149 Reagent Kit (cat #C34880).

150

151

2.2 Whole genome bisulfite sequencing

All DNA samples were sonicated to ~350bp with a peak power of 175, duty of 10%, 200
 cycles/burst, and a time of 47 seconds. The sonicated DNA was cleaned and
 concentrated with Zymo gDNA clean and concentrator columns and eluted in 25 μl EB.

Bisulfite conversion was performed with the Zymo EZ DNA Methylation Lightning Kit (cat
#11-338) using ~35 ng of each sonicated sample. Libraries were prepared using the Swift
ACCEL-NHS MethylSeq DNA Library Kit (cat #30096) with 7 cycles of PCR for normalinput samples and 11 cycles for low-input samples. Libraries were pooled and a 0.85X
SPRI cleanup was performed on 250 µl of the pool, eluted in 100 µl. The library pool
(concentration of 3.63 ng/ µl) was sequenced across 4 lanes of an Illumina NovaSeq 6000
S4 flow cell using 150 bp paired end reads.

162

163 FASTQ files for each sample were merged across lanes using FASTQ Me (19) and 164 aligned to the hg38 genome using CpG Me (20) with the default parameters (21-24). The 165 alignment pipeline includes trimming adapters and correcting for methylation bias, 166 screening for contaminating genomes, aligning to the reference genome, removing PCR 167 duplicates, calculating coverage and insert size, and extracting CpG methylation to 168 generate a cytosine report (CpG count matrix) and a quality control (QC) report. Global 169 methylation for each sample was calculated as the total number of methylated CpG 170 counts divided by the total number of CpG counts from CpG count matrices. From the 90 171 samples sequenced, four samples were removed from analysis: two due to high levels of 172 sequence duplication and two due to missing sample data.

173

2.3 Genome-wide DNA methylation arrays

In addition to WGBS, existing DNA methylation data was available from NDBS for each
sample from Illumina Infinium MethylationEPIC (EPIC) DNA methylation arrays (17). In
brief, DNA was isolated from a separate one-third portion of the NDBS, bisulfite
conversion performed as above, and DNA samples were block-randomized (ensuring
equivalent distribution of sex and race/ethnicity on each plate) for EPIC arrays (17). QC

of DNA methylation array data was conducted in R using "minfi", "SeSAMe", and "noob"
 packages, and trisomy 21 was confirmed from copy-number variation plots generated
 using the "conumee" package, as described (17). DMRs associated with DS-CHDs were
 investigated using the ipDMR method with the ENmix R package (25).

184

185 **2.4 Cell type estimation**

To estimate nucleated cell proportions in NDBS samples, we used the EPIC array data to perform reference-based deconvolution using the Identifying Optimal Libraries (IDOL) algorithm (26). Briefly, "estimateCellCounts2" function from the "FlowSorted.Blood.EPIC" R package was used to estimate proportions of CD8+ T lymphocytes (CD8T), CD4+ T lymphocytes (CD4T), natural killer (NK) cells, B lymphocytes (B cell), monocytes, granulocytes, and nucleated red blood cells (nRBC), using cord blood cell reference samples included in the "FlowSorted.CordBloodCombined.450k" R package.

193

194 **2.5 Sample trait analysis**

195 Newborn sample traits of global CpG methylation, birthweight, gestational age of delivery, 196 age of blood collection, race, ethnicity, and cell type proportions were correlated using 197 Pearson's method with the Hmisc package v4.7.1 and p-values were adjusted by FDR 198 (0.05 threshold) using the corr.test function in the Psych package v2.2.9 in Rv4.1.3. DS-199 CHD vs DS non-CHD samples (sex-combined and sex-segregated) were tested for 200 differences across sample traits using Welch's unpaired variances t-test with GraphPad 201 Prism v9.4.1. Stepwise forward logistic regression was performed to determine the 202 variables that best predicted CHD in each sex using the glm (family = binomial) function 203 in R v4.1.3. Stepwise linear regression was performed to determine the variables that 204 best predicted global CpG methylation in each sex using the Im function in R v4.1.3.

206 **2.6 DMR** analysis from WGBS

207 DMRs for DS-CHD vs DS non-CHD in the WGBS data were called for Sex Combined, 208 Females Only, and Males Only samples using DMRichR v1.7.3 (16) and R version 4.1.0. 209 Default parameters were used to identify DMRs containing at least 5 CpGs with at least a 210 5% methylation difference between groups, with each CpG requiring at least 1x coverage 211 in at least 75% of samples. DMRichR uses bsseq (27) to extract methylation levels from 212 cytosine reports and dmrseq (28) to identify DMRs. The dmrseq algorithm detects 213 candidate regions whose smoothed pooled methylation proportion show differences 214 between groups, then assesses the significance of candidate regions through permutation 215 testing of the pooled null distribution to calculate p-values that are then FDR corrected to 216 generate q-values (28). In all three comparisons (Sex Combined, Females Only, and 217 Males Only), we adjusted for sample traits that were correlated with global methylation (|r| 218 >0.2): age of blood collection and all cell types. Sex was additionally adjusted for in the 219 Sex Combined analysis. Gestational age and birthweight met this cut-off in males, but not 220 females, and were not corrected for because the effect of gestational age on DNA 221 methylation has been found to mostly be due to nRBC proportion (29) and birthweight is 222 largely dependent on gestational age. Sex chromosomes were included in Females Only 223 and Males Only comparison but not the Sex Combined comparison. The sex of each 224 sample was confirmed by the number of reads of sex chromosomes as previously 225 described (16).

226

Principal component analysis (**PCA**) was performed using smoothed methylation values over the DMRs identified in each comparison to test for separation of CHD and non-CHD samples. Data was standardized so each variable had a mean of 0 and standard deviation of 1, and principal components were selected by parallel analysis from 1000 permutations using GraphPad Prism v9.4.1. The two principal components that explained the greatest

variance in the data were selected for graphing and samples were color-coded by CHD
and non-CHD. Sex specificity of the DMRs was tested by obtaining smoothed methylation
values over DMRs from the Males Only comparison in female samples and over DMRs
from the Females Only comparison in male samples, and PCA was performed as
explained above.

237

Machine learning algorithms implemented through DMRichR were used to identify minimal DMRs for classifying samples as CHD or non-CHD (16). Random forest algorithms from the Boruta package (30) and support vector machine algorithms from the sigFeature package (31) were used to build binary classification models and rank the DMRs by importance for the feature selection analyses. Minimal DMRs were selected as those that were identified in both lists and were in the top 1%.

244

DS-CHD DMRs from Sex Combined, Females Only, and Males Only comparisons were
 overlapped by genomic coordinates using rtracklayer v1.54.0 (32) and GenomicRanges
 v1.46.1 (33), and the venn diagram was made with VennDiagram v1.7.3 (34) in R v4.1.3.

248

249 **2.7 Enrichment testing and gene ontology from WGBS DMRs**

DMRs from all comparisons were tested for enrichment in chromosome location compared to background regions using the Database for Annotation, Visualization and Integrated Discovery (DAVID), 2021 version (35,36). DMRs were tested for enrichment in genic (promoter, 5'UTR, exon, intron, 3'UTR, downstream, intergenic) and CpG (island, shore, shelf, open sea) contexts compared to background regions using DMRichR (16). The significance of genic and CpG annotations were tested using Fisher's exact test and FDR correction. DMRs were mapped to genes on the hg38 genome using TxDb. Gene

- 257 ontology enrichment was performed using rGREAT (37), with genomic coordinates of
 258 DMRs tested relative to background regions using the "oneClosest" rule.
- 259

260 **2.8 Replication of WGBS CHD DMRs in independent DS newborn study**

- 261 DMRs were tested for replication in a previously published DS NDBS WGBS dataset with 262 10 non-CHD (2 female, 8 male) and 11 CHD (6 female, 5 male) individuals (16). 263 Unadjusted smoothed methylation values were calculated in replication dataset samples 264 over DMR genomic coordinates from Sex Combined, Females Only, and Males Only 265 comparisons using the getMeth function of the bsseq R package (27). Unpaired t-tests 266 were calculated using the smoothed methylation values for replication CHD vs non-CHD 267 samples and *p*-values were corrected by FDR using GraphPad Prism v9.4.1.
- 268

269 2.9 Comparison of WGBS CHD DMRs and background regions with DS vs TD NDBS 270 samples

271 DS-CHD DMRs and background regions were tested for overlap with DMRs associated 272 with DS in a previous epigenome-wide association study that included 21 DS (8 female, 273 13 male) and 32 TD (16 female, 16 male) NDBS samples with WGBS data (16). 274 Unadjusted smoothed methylation values were calculated in replication dataset samples 275 over DMR and background region genomic coordinates from Sex Combined, Females 276 Only, and Males Only analyses using the getMeth function of the bsseg R package (27). 277 Unpaired t-tests were calculated for DS vs TD using the smoothed methylation values of 278 the replication dataset and p-values were corrected by the FDR method using GraphPad 279 Prism v9.4.1. Potential differences between the proportions of DS-CHD DMRs and 280 background regions that were significantly differentially methylated in DS vs TD or methylated in the same direction in DS vs TD as DS-CHD vs DS non-CHD were calculated 281 282 using the z-test for two population proportions.

283

3. Results

3.1 Sample traits were not different in DS-CHD cases compared to DS non-CHD controls

287 We quantitated DNA methylation by EPIC array and WGBS in DNA isolated from NDBS 288 from 86 individuals with DS, 45 of whom also had a CHD. Overall, our cohort had more 289 females (n = 54, CHD = 27, non-CHD = 27) than males (n = 32, CHD = 18, non-CHD = 290 14) and a high proportion of Hispanic participants (n = 57 (63%)), compared to non-291 Hispanic white (n = 17 (19.8%)), non-Hispanic Asian (n = 8 (9.3%)), and non-Hispanic 292 Black (n = 4 (4.7%)) participants; however, there were no significant differences for sex or 293 race/ethnicity between DS-CHD and DS non-CHD newborns (Table 1) (Supplemental 294 Table S3). In addition, birthweight, gestational age, and age at blood collection did not differ significantly between DS-CHD and DS non-CHD newborns (Table 1) 295 296 (Supplemental Table S3).

297

298 The estimated cell type proportions (CD8T, CD4T, NK, B cell, monocytes, granulocytes, 299 nRBC) in newborn blood were highly variable across samples, particularly for nRBC and 300 granulocyte proportions (Supplemental Table S2). All cell types were positively 301 correlated with one another, except nRBCs which were negatively correlated with all other 302 cell types (Supplemental Table S4) (Supplemental Figure S1). Most cell types (CD8T, 303 CD4T, NK, monocytes, nRBC) were also significantly (unadjusted p < 0.05) correlated with 304 age of blood collection and all cell types were significantly correlated with WGBS global 305 methylation levels, supporting the adjustment for cell types in our DMR analyses. Cell type 306 proportions did not differ significantly between DS-CHD and DS non-CHD newborns 307 overall, or in sex-stratified comparisons (Table 1) (Supplemental Table S3).

309 310

Table 1. Sample traits in DS-CHD cases and DS non-CHD controls

	All samples (<i>n</i> = 86)	DS-CHD (<i>n</i> = 45)	DS non-CHD (<i>n</i> = 41)
	Mean or <i>n</i> (SD or %)	Mean or <i>n</i> (SD or %)	Mean or <i>n</i> (SD or %)
Global methylation	79.3 (3.9)	79.0 (4.3)	79.5 (3.4)
CD8T	0.05 (0.03)	0.05 (0.03)	0.05 (0.04)
CD4T	0.12 (0.08)	0.13 (0.09)	0.11 (0.07)
NK	0.03 (0.02)	0.03 (0.03)	0.03 (0.02)
B cells	0.007 (0.009)	0.006 (0.009)	0.007 (0.01)
Monocytes	0.07 (0.04)	0.07 (0.05)	0.07 (0.04)
Granulocytes	0.58 (0.21)	0.54 (0.23)	0.63 (0.17)
nRBCs	0.12 (0.23)	0.15 (0.27)	0.09 (0.19)
Birthweight (grams) ¹	3018 (633)	2953 (636)	3092 (630)
Gestational age (days) ²	266 (17)	266 (16)	267 (18)
Age of blood collection (hours)	62 (57)	63 (49)	62 (65)
Sex			
Female	54 (62.8%)	27 (60%)	27 (65.9%)
Male	32 (37.2%)	18 (40%)	14 (34.1%)
Race/ethnicity			
Asian (non-Hispanic)	8 (9.3%)	6 (13.3%)	2 (4.9%)
Black (non-Hispanic)	4 (4.7%)	3 (6.7%)	1 (2.4%)
White (non-Hispanic)	17 (19.8%)	9 (20%)	8 (19.5%)
Hispanic	57 (66.3%)	27 (60%)	30 (73.2%)

311312

¹ Missing data from 1 sample (DS non-CHD)

² Missing data from 5 samples (4 DS-CHD, 1 DS non-CHD)

313 314

315 3.2 WGBS of newborn blood DNA detects global hypomethylation in DS-CHD males 316 compared to DS non-CHD males due to elevated nRBC proportions

317 To assess the reproducibility of EPIC array and WGBS methylation quantitation, we 318 examined global CpG methylation levels from the two platforms and found that EPIC array 319 beta values (Supplemental Table S5) were lower than WGBS global methylation values 320 across all samples, but very strongly correlated (r = 0.9716, p < 0.0001) (Supplemental 321 Figure S2). While a few samples had notably low global CpG methylation levels (<70% 322 from WGBS), these samples were not removed from analysis because their other QC 323 metrics were acceptable and their corresponding array beta values were also low, 324 suggesting it was not a technical error.

325

326 Using WGBS data, we first assessed whether global CpG methylation levels differed 327 between DS-CHD and DS non-CHD newborns. There was no significant difference 328 overall, but when stratified by sex we found significant hypomethylation in DS-CHD males 329 compared with DS non-CHD males (unadjusted p < 0.05), a pattern that was not seen in 330 females (Figure 1A-B) (Supplemental Figure S3) (Supplemental Table S3). We 331 confirmed by logistic regression that global methylation was the most predictive variable 332 of CHD in males (p = 0.101), while CD4T cell proportion was the most predictive variable 333 in females (p = 0.0681) (Supplemental Table S6). Because nRBCs are known to have 334 lower methylation levels than other cell types in blood (38) and their proportion in blood 335 samples varies widely across individuals (39) in negative association with global 336 methylation (38,40), we investigated the relationship between nRBC proportion and global 337 methylation in our samples. In both females and males, nRBC proportion was significantly 338 negatively correlated with global methylation levels (Figure 1C-D) (Supplemental Table 339 S4) (Supplemental Figure S1) and was the most predictive variable of global methylation 340 in linear regression models (females p < -2E16, males p = 2.12E-9) (Supplemental Table 341 **S6).** Presence of CHD predicted global methylation levels in males (p = 0.0618) much 342 better than in females (p = 0.981), but addition of nRBC proportion as an adjustment 343 covariate decreased the strength of this relationship (males, p = 0.237) (Supplemental 344 Table S6).

345

While proportion of nRBCs in the nucleated cell population is typically very low, with a median of 0 for the estimated nRBC proportions across samples in our study, we identified 12 out of 32 male samples with nRBC proportions >1%, of which 10 (83%) had a CHD (Supplemental Table S2) (Supplemental Figure S3). In contrast, we identified 24/54 females with nRBC proportions >1% of which only 50% (n=12) had a CHD. In a sensitivity

analysis, we removed five male samples that had notably high nRBC levels (>20%) and corresponding low global methylation levels and saw that global methylation in DS-CHD vs DS non-CHD male samples were no longer significantly different (p = 0.1865) (Supplemental Table S3). Females showed high interindividual variation in global methylation levels and nRBC proportions in both CHD and non-CHD groups, while CHD males showed much more variation (similar to females) than non-CHD males (Supplemental Figure S3).





Figure 1. Global hypomethylation in DS-CHD males vs DS non-CHD males is driven by
 samples with high nRBC proportions. Density plot of average percent smoothed
 methylation in DS-CHD (Yes: blue) and DS non-CHD (No: red) in A) females (note that red
 and blue lines are overlapping) and B) males. Percent global methylation correlated with

nRBC proportion in **C**) females (Pearson's r = -0.93, p = 2.16E-24) and **D**) males (Pearson's r = -0.84, p = 2.13E-9)

366

367 3.3 Sex-stratified DMRs distinguish DS-CHD from DS non-CHD samples better than 368 sex-combined DMRs

Next, using WGBS data we investigated whether there were DMRs associated with DS-CHDs in Sex Combined, Females Only, and Males Only comparison groups to characterize both sex-specific and sex-independent patterns in DS-CHD methylation. We adjusted for confounding variables that were associated with global methylation (|r| >0.2): age of blood collection and all cell type proportions, as well as sex (specific for the Sex

- 374 Combined comparison) (Supplemental Figure S2) (Supplemental Table S4).
- 375

The Sex Combined comparison yielded 58 significant by permutation (*p* <0.05) DMRs (Supplemental Table S7). In Females Only, we found 341 DMRs (Supplemental Table S8), whereas in Males Only we found 3,938 DMRs (Figure 2A) (Supplemental Table S9). Samples with low methylation levels across Males Only DMRs corresponded with those with low global methylation. In a sensitivity analysis excluding the five male samples with nRBC proportions >20%, we identified 2,474 Males Only DMRs (Supplemental Table S10).

383

DMR hierarchal clustering and principal component analysis (PCA) showed that CHD and non-CHD samples did not separate completely, although sex stratification improved the distinction (Figure 2A-B). Using machine learning feature selection, we identified a minimal set of 19 Males Only DMRs that could distinguish CHD from non-CHD samples (Figure 2C) (Supplemental Table S11). The five male samples with high nRBCs and low methylation across DMRs did not have outlier methylation values across the 19 minimal DMRs, showing that the most predictive DMRs were not driven by outliers. In the Males

391 Only sensitivity analysis (with 5 samples with nRBC >20% removed), 13 minimal DMRs 392 distinguished CHD from non-CHD, with four overlapping with those from the Males Only 393 minimal selection using all samples: *DCAF1, LARGE2, LOC105379273, SYT9* 394 **(Supplemental Table S11).** In the other comparisons, 6 Sex Combined and 3 Females 395 Only DMRs were identified by the feature selection but could not cleanly distinguish CHD 396 from non-CHD samples **(Supplemental Figure S4) (Supplemental Table S11).**

397

398 In the replication dataset of WGBS from NDBS of 21 children with DS, 11 with CHD (6 399 females, 5 males) and 10 without CHD (2 females, 8 males) (16), we found 26 (46.4%) of 400 the 56 Sex Combined DMRs that were covered in the replication study were methylated 401 in the same direction in both groups (Supplemental Table S12), while 161/329 (48.9%) 402 of Females Only (Supplemental Table S13) and 2,229/3,938 (56.7%) of Males Only 403 DMRs (Supplemental Table S14) were methylated in the same direction. Few DMRs 404 were significantly differentially methylated (unadjusted p < 0.05) in the replication dataset, 405 with 2 Sex Combined, 9 Females Only, and 68 Males Only meeting this cutoff.

406

In DMR analysis using EPIC array data, there were no significant DMRs associated with
DS-CHDs, likely due to the EPIC array only covering ~3% of CpGs covered by WGBS
(data not shown).



410

411 Figure 2. DMR profiles of CHD vs non-CHD in Sex Combined, Females Only, and

412 Males Only comparisons within DS. A) Heatmaps of nominally significant (*p* < 0.05) DMRs

413 from DS-CHD vs DS non-CHD samples in Sex Combined. Females Only, and Males Only 414 comparisons. All heatmaps show hierarchical clustering of Z-scores, which are the number of standard deviations from the mean of non-adjusted percent smoothed individual 415 416 methylation values for each DMR. **B)** PCA analysis using the smoothed methylation values 417 of all DMRs from the Sex Combined and Females Only comparisons and the 1000 most 418 significant DMRs in the Males Only comparison. C) Hierarchical clustering heatmap of the 419 machine learning feature selection analysis of the consensus DMRs from the Males Only 420 comparison.

421

422 **3.4 DS-CHD DMRs are sex-specific, with a small fraction overlapping across sexes**

423 We next examined similarities and differences in DMRs across females and males. In the 424 Sex Combined comparison, 60% of DMRs were hypomethylated in CHD compared to 425 non-CHD samples, while 40% of Females Only DMRs and 96% of Males Only DMRs were 426 hypomethylated (Figure 3A). In our Males Only sensitivity analysis that removed samples 427 with nRBC proportions >20%, 82% of DMRs were hypomethylated. To test the sex 428 specificity of Females Only and Males Only DMRs, we analyzed the smoothed methylation 429 values over DMRs from the Males Only comparison in female samples and from the 430 Females Only comparison in male samples and found that CHD and non-CHD samples 431 did not separate by PCA (Supplemental Figure S5). Females and males also did not 432 separate by hierarchal clustering or PCA in the Sex Combined comparison (Figure 2A) 433 (Supplemental Figure S6).

434

DMR genomic coordinates from all comparisons were then overlapped to identify sexspecific vs sex-independent regions. Only 4 DMRs overlapped across all three comparisons, 22 across Sex Combined and Females Only comparisons, 10 across Sex Combined and Males Only comparisons, and 4 across Males Only and Females Only comparisons (Figure 3B). All overlapping DMRs between comparison groups were methylated in the same direction except for the 4 overlapping between Females Only and Males Only comparisons (but not the Sex Combined comparison), which showed

442 methylation in opposite directions (**Figure 3C**). The 4 DMRs identified in all three 443 comparisons mapped to *CDH22*, *ZNF890P*, *DIRC3*, and *TTLL10-AS1* genes.



444

445 Figure 3. Overlapping CHD DMRs across Sex Combined, Female Only, and Male Only 446 comparisons within DS. A) The percent of DMRs which were hypermethylated versus 447 hypomethylated in each of the three comparisons. B) Venn diagram reflecting the numbers 448 of unique and overlapping DMR genomic coordinates across the three comparisons. C) DS-449 CHD DMRs which overlap in two or more comparisons mapped to genes. Red indicates 450 hypermethylation in CHD compared to non-CHD while blue represents hypomethylation. 451 with stronger shades representing a greater percent methylation difference. Grey is used 452 when a DMR was not called for that comparison. Black dots indicate methylation in the

same direction in the discovery and replication datasets (10 non-CHD (2 female, 8 male))
and 11 CHD (6 female, 5 male)) while white dots indicate methylation in the opposite
direction in the two datasets. No dot means that the DMR genomic coordinates were not
covered in the replication dataset.

458 3.5 DS-CHD DMRs are enriched for gene exons, CpG islands, and bivalent chromatin 459 CHD DMRs from Sex Combined, Females Only, and Males Only comparisons were 460 analyzed for enrichment compared to background regions by distribution across 461 chromosomes, genic and CpG contexts, histone marks, and chromatin states. In all three 462 comparisons, DMRs were distributed throughout the genome (Supplemental Figure S7), 463 though Males Only DMRs showed significant enrichment (FDR <0.05) on chromosomes 464 2, 4, 5, 8, 18, and 21, while Females Only DMRs showed nominal enrichment (unadjusted 465 p < 0.05) on chromosomes 20, X, and 21 (Supplemental Table S15). There was 466 significant positive enrichment in all comparisons for gene exons and CpG islands (Figure 467 4) (Supplemental Figures S8, S9) (Supplemental Table S16), as well as the 468 transcriptionally repressive H3K27me3 histone mark and bivalent enhancers and 469 transcription start sites based on chromatin states (Supplemental Figures S10-S15). Sex 470 differences were also observed, with significant positive enrichment for CpG shelves in 471 the Females Only comparison and significant negative enrichment in the Males Only 472 comparison. The Females Only DMRs also showed enrichment for H3K4me3, associated 473 with active/poised chromatin, while the Males Only DMRs showed enrichment for 474 H3K9me3, another repressive mark (Supplemental Figure S13). Hypomethylated 475 regions showed overall stronger enrichment for histone marks and chromatin states 476 compared to hypermethylated regions (Supplemental Figures S14-S15).



477

478Figure 4. Annotation enrichments of CHD DMRs. A) Genic and B) CpG enrichments of479all significant (p < 0.05) DMRs from Sex Combined, Females Only, and Males Only480comparisons. DMRs were compared to background regions for each comparison and481significance was determined by the Fisher's test and FDR correction. * = q < 0.05.</td>

482

483 **3.6 DS-CHD DMRs map to genes that are enriched for cardiac terms**

484 DMRs mapped to genes were analyzed for enrichment across Gene Ontology terms (*p* 485
 <0.05) related to biological processes, cellular components, and molecular functions. All
486 comparisons showed enrichment for heart-related terms, such as cardiac muscle

494	Combined) (Figure 5).
493	related biological processes, such as platelet activation and innate immune response (Sex
492	PDE4D, ACVR1, GATA4, and others (Table 2). Enriched terms also included immune-
491	S19). Genes contributing to the heart-related terms included FGF12, PIK3CA, TNNI3,
490	can lead to AVSD (Males Only) (Supplemental Figure S16) (Supplemental Tables S17-
489	primum, which divides the heart atrium into left and right and whose developmental failure
488	formation of the embryonic heart tube (Females Only), and development of the septum
487	contraction (Sex Combined) (Figure 5), dorsal/ventral pattern formation, which includes



495

496 Figure 5. Gene ontology enrichments. Bar plot of the fifteen most significant GO
 497 enrichments for biological processes in DS-CHD versus DS non-CHD DMRs from the Sex
 498 Combined comparison.

500 Table 2. Heart-related biological processes identified from DMR Gene Ontology

Comparis	GO Term	Genes
on		
Sex	cardiac muscle contraction	FGF12,PIK3CA,TNNI3
Combined		- , , -
	striated muscle contraction	FGF12,PIK3CA,TNNI3
	heart contraction	FGF12,PIK3CA,TNNI3
	heart process	FGF12,PIK3CA,TNNI3
	ductus arteriosus closure	TFAP2B
	determination of	NBL1
	dorsal/ventral asymmetry	
	cellular response to	CD40
	erythropoietin	
	regulation of cardiac	NPR2,TNNI3
	conduction	
	muscle contraction	FGF12,PIK3CA,TNNI3
	skeletal muscle contraction	TNNI3
Females	dorsal/ventral pattern	FOXG1,GLI2,GREM2,INTU,MDFI,SMAD6,S
Only	formation	UFU,TCTN1
	negative regulation of	PDE4D
	relaxation of cardiac muscle	
	negative regulation of heart	AGTR2,PDE4D
	adrenergic receptor	PDE4D
	in boart process	
	regulation of heart rate by	
	chemical signal	
	regulation of relaxation of	PDF4D
	cardiac muscle	
	aorta development	SMAD6,SUFU,TFAP2B,TGFB2
	regulation of ventricular	ANK2,WDR1
	cardiac muscle cell	
	membrane repolarization	
Males Only	septum primum	ACVR1,GATA4,GJA5,SOX4,TGFB2
	development	
	atrial septum primum	ACVR1,GATA4,SOX4,TGFB2
	morphogenesis	
	atrioventricular canal	CHD7,FOXN4,HAS2,PTPN11
	development	
	adult heart development	ADRA1A,CHD7,HAND2,SCUBE1,TCAP
	artery smooth muscle	AGT,EDN1,EDN2,HTR2A,MKKS
	contraction	0/107
	right ventricular compact	CHD7
	myocardium	
		CATAA
	amai sepium secundum morphogenosis	
	norphogenesis	
	rate	PDF4D RYR2 SCN3R
		TACR3.UTS2

cardiac muscle hypertrophy	AGT,GATA4,GATA6,HDAC4,KDM4A,LEP,P
	PP3CA,RYR2,TCAP,TIAM1,TTN
positive regulation of heart	ADRA1A,ADRB1,EDN1,EDN2,EDN3,KCNQ1
contraction	,PDE4D,RGS2,RYR2,SCN3B,TACR3,TGFB2
	,UTS2
septum secundum	GATA4
development	
cardiac septum	ACVR1,BMP4,BMP7,CHD7,FZD1,FZD2,GAT
morphogenesis	A4,GATA6,GJA5,HES1,HEY1,HEYL,ISL1,JA
	G1,MSX2,NRP1,PARVA,PITX2,PROX1,RAR
	B,SMAD6,SMAD7,SOX11,SOX4,TBX3,TGF
	B2.TGFBR2.ZFPM2

501

3.7 DS-CHD DMRs are also differentially methylated in DS vs typical development

503 NDBS

504 DS-CHD DMRs were tested for comparison in previously published DS vs TD NDBS 505 WGBS samples (16) to evaluate the hypothesis that if DS-CHD is a more severe form of 506 DS, CHD DMRs should be partially shared with DS vs TD DMRs (Table 3). Of the 58 Sex 507 Combined CHD DMRs, 16 (27.6%) were significantly differentially methylated (p < 0.05) in 508 DS vs TD samples (Supplemental Table S20), 9 of which (56.3%) were methylated in 509 the same direction in DS vs TD samples as DS-CHD vs DS non-CHD samples. Of 510 Females Only DMRs, 42/341 (12.3%) were significantly differentially methylated (p < 0.05) 511 in DS vs TD, with 28 (66.7%) methylated in the same direction (Supplemental Table S21) 512 and of Males Only DMRs, 602/3,938 (15.3%) were significantly differentially methylated 513 (p < 0.05) in DS vs TD, with 528 (87.7%) methylated in the same direction (Supplemental 514 Table S22). These numbers decreased in a sensitivity analysis with the Males Only DMRs 515 generated with five samples with nRBC >0.2 removed, where 334/2,454 (13.6%) covered 516 DMRs were significantly (p < 0.05) differentially methylated in DS vs TD male samples, of 517 which 248/334 (74.3%) were methylated in the same direction. For all three comparisons, 518 there was a trend towards more CHD DMRs being significantly differentially methylated in 519 DS vs TD samples compared to background regions (z-test for two population proportions. 520 Sex Combined p = 0.08364, Females Only p = 0.0536, Males Only p = 0.0601) (Figure 6A).

521 In Males Only, significantly more DMRs were methylated in the same direction in DS vs 522 TD as DS-CHD vs DS non-CHD compared to background regions (z-test for two 523 population proportions, p < 0.00001), though this was not true for Sex Combined or 524 Females Only CHD DMRs (Figure 6B). Of DMRs that were significantly differentially 525 methylated (q < 0.05) in DS vs TD samples, 5/9 (55.6%) Sex Combined, 6/8 (75%) 526 Females Only, and 15/16 (93.85%) Males Only DMRs were hypomethylated in DS 527 compared to TD samples. With the exception of an exon in ZNF735, which was 528 significantly hypermethylated (q < 0.05) in both the Sex Combined and Females Only DS 529 vs TD comparisons, all DMRs were specific to one comparison (Figure 6C).

530

Table 3. Significance and direction of CHD DMRs and background regions in DS vs TD samples

532	
533	

531

	DMRs	Background Regions
Sex Combined	n (%)	n (%)
Total	58	5,363
Omitted	0	28
<i>p</i> < 0.05	16 (27.6)	995 (18.7)
<i>p</i> ≥ 0.05	42 (72.4)	4,340 (81.3)
Same direction	34 (58.6)	3,274 (61.4)
Opposite direction	24 (41.4)	2,061 (38.6)
Females Only	n (%)	n (%)
Total	341	11,998
Omitted	2	147
<i>p</i> < 0.05	42 (12.4)	1,101 (9.3)
<i>p</i> ≥ 0.05	297 (87.6)	10,750 (90.7)
Same direction	172 (50.7)	6,304 (53.2)
Opposite direction	167 (49.3)	5,547 (46.8)
Males Only	n (%)	n (%)
Total	3,938	127,819
Omitted	26	1,413
<i>p</i> < 0.05	602 (15.4)	18,099 (14.3)
<i>p</i> ≥ 0.05	3,310 (84.6)	108,307 (85.7)
Same direction	3,001 (76.7)	90,954 (72.0)
Opposite direction	911 (23.3)	35,452 (28.0)

534

535 Same direction indicates methylation is in same direction (hypo or hyper) in DS vs TD as in 536 DS-CHD vs non-CHD



537

538	Figure 6. Comparison of DS-CHD DMRs with DS vs TD samples. A) Percent of DS-CHD
539	DMRs and background regions that were significantly differentially methylated in DS vs TD
540	samples. Z-test for two population proportions, Sex Combined ($z = 1.7343$, two-tailed $p =$
541	0.08364) Females Only (z =1.93, two-tailed p =0.0536), Males Only (z =1.8808, two-tailed p
542	=0.0601). + = $p < 0.1$. B) Percent of DS-CHD DMRs that were methylated in same direction
543	in DS vs TD as in DS-CHD vs DS non-CHD. Z-test for two populations proportions, Sex
544	Combined (z =-0.4274, two-tailed p =0.6672), Females Only (z =-0.8936, two-tailed p
545	=0.37346), Males Only (z = 6.5357, two-tailed p <0.00001). **** = p <0.00001. C) Heatmap
546	showing DS-CHD DMRs that were significant (q < 0.05) in DS vs TD samples mapped to
547	genes. Red indicates hypermethylation in CHD compared to non-CHD while blue represents
548	hypomethylation, with stronger shades representing a greater percent methylation difference
549	and gray meaning that that DMR was not significant for that comparison. Black dots indicate
550	that methylation is in the same direction for DS vs TD as DS-CHD vs DS non-CHD while
551	white dots indicate methylation is in the opposite direction.
552	

553 4. Discussion

- 554 This is the largest study to date to investigate epigenetic variation associated with CHDs in
- 555 individuals with DS. Although non-syndromic CHDs have been widely studied, there has been

556 relatively little research into the etiology and biomarkers of CHDs in individuals with DS. 557 despite nearly half of the DS population presenting this phenotype (2-5). To address this gap, 558 we assessed DS-CHD methylation in DNA isolated from NDBSs, an understudied and 559 accessible biospecimen that enables the analysis of epigenomic changes during the in utero 560 and perinatal periods that are associated with phenotypic traits of interest. We confirmed the 561 reproducibility of DNA extraction and bisulfite conversion from NDBSs by finding a high 562 correlation (r = 0.9716) between global methylation levels from WGBS and EPIC array, which 563 used different punches from the same blood spots.

564

565 Although newborn blood typically shows ~79-84% global CpG methylation from WGBS 566 (16,40), we found a range of 60.8-82.9% in our NDBS DNA. The samples with notably low 567 WGBS global methylation also had low EPIC array beta values and passed other QC metrics, 568 indicating that technical errors do not explain the result, although we cannot exclude non-569 biological causes. Previous studies have found a trend towards global hypomethylation in DS 570 compared to TD NDBS (16), which may explain our findings. We further found that global 571 methylation was lower in DS-CHD males compared to DS non-CHD males, though this 572 relationship was not found in females. Global methylation was strongly negatively correlated 573 with, and predicted by, nRBC proportion in both sexes. Although nRBCs typically constitute a 574 very small proportion of nucleated cells, we found nRBC proportions ranged widely in both 575 sexes and were evenly spread amongst CHD and non-CHD females but in males, 10/12 576 samples with nRBC >1% were CHD positive. This discrepancy in the relationship between 577 high nRBCs and CHD in males versus females likely explains the association between CHD 578 and global hypomethylation in males and the lack of such association among females, given 579 the strong effects of nRBC proportions on global methylation levels in DS newborns (17). The 580 etiology of the male-specific association between high nRBCs and CHD in newborns with DS 581 remains to be determined.

582

583 Previous studies have reported high nRBC levels in DS newborns with pulmonary 584 hypertension (41), as well as in hypoxic-related pregnancy situations, such as preeclampsia, 585 maternal obesity and diabetes, maternal smoking, and prenatal exposure to infection (42-48). 586 Increased nRBC counts are thought to follow fetal hypoxemia through elevated erythropoietin 587 (EPO), a hormone that stimulates production of erythrocytes (red blood cells) in an effort to 588 increase oxygen delivery to tissues (49,50). Interestingly, EPO is higher in children with DS-589 CHD compared to non-syndromic CHD (51). Because CHDs reduce cerebral oxygen (52) 590 and may induce fetal hypoxemia (53), high nRBC proportions may be more common in 591 individuals with CHDs and, in particular, in DS newborns with CHDs given the placental 592 abnormalities seen in fetuses with trisomy 21 (PMID: 31683073). However, we could not 593 confirm this hypothesis with our sample size. Moreover, nRBC proportions were estimated 594 from DNA methylation array data, rather than using actual cell counts, and cell type 595 deconvolution in individuals with DS may be confounded by the presence of blast cells that 596 are common in DS and not accounted for in the analysis (17). Cell composition deconvoluted 597 from DNA methylation arrays has been previously reported to be altered in DS blood 598 compared to non-DS blood (54). Further, we previously reported a positive relationship 599 between high nRBC proportions in newborns with DS and presence of somatic GATA1 600 mutations, indicative of transient abnormal myelopoiesis (TAM) or silent TAM, and it is 601 possible that the relationship between CHD and global hypomethylation in males may be 602 confounded by this preleukemic condition (17). Understanding of the complex relationships 603 between CHDs in DS, global methylation, cell type proportions, sex, and fetal hypoxia would 604 benefit from further investigation.

605

In our WGBS regional analysis, we found over 10-fold the number of CHD-associated DMRs
 in DS males than in females, and even fewer DMRs in the Sex Combined analysis. Reflecting

608 our finding of global hypomethylation in CHD males, 96% of Males Only DMRs were 609 hypomethylated, a pattern not seen in the Females Only or Sex Combined analyses. All DMRs 610 were corrected for confounding factors including cell type proportions, suggesting that nRBC 611 levels were not fully responsible for the notable proportion of hypomethylated DMRs in males, 612 although we cannot rule out residual confounding due to nRBCs or unmeasured traits related 613 to nRBCs. Additionally, removing the five male samples with nRBC proportions > 20% 614 resulted in 82% hypomethylated DMRs, suggesting that these five samples alone were not 615 driving the signature of hypomethylation in DS-CHD males. Some DMRs from all comparisons 616 were also differentially methylated in DS vs TD samples, and in males, a significantly higher 617 proportion of DMRs were methylated in the same direction in DS vs TD and DS-CHD vs DS 618 non-CHD compared to background regions. These results suggest that male DS patients with 619 CHD may represent a more severe epigenomic signature than is observed for DS versus TD, 620 although this may also reflect the higher nRBC proportions that have been reported in 621 newborns with DS than in TD newborns (Muskens 2021). In contrast, female DS cases with 622 CHD are somewhat epigenetically distinct from female and male DS cases without CHD. 623 Response to hypoxia may play a role in these differences. DS newborns, even those without 624 CHDs, experience more hypoxemia events than newborns with TD (55), and CHDs further 625 induce fetal hypoxemia (53). A wide variety of sex differences have been observed in 626 response to hypoxia in both humans and animal models (56,57), including differences in gene 627 expression profiles of female vs male mice in cardiac adaptive responses to hypoxia (58). 628 These sex-specific responses to hypoxia may be reflected in the methylome, which is known 629 to be influenced by gestational hypoxia (59) (reviewed in (60)). Identification of genes and 630 pathways whose methylation and/or gene expression is altered in DS, CHDs, and hypoxia 631 may help elucidate the sex specificity of molecular mechanisms related to DS-CHD.

632

633 Although we did not find any significant DMRs associated with DS-CHD after FDR-correction, 634 the nominally significant DMRs were enriched for genes implicated in cardiac processes, 635 suggesting that at least some of the DMRs may reflect true epigenetic mechanisms associated 636 with DS-CHD development. In particular, Males Only DMRs selected by machine learning 637 feature selection were able to distinguish CHD from non-CHD samples and frequently 638 mapped to genes associated with CHDs or cardiomyopathies, including FUNDC1 (61), ETV5 639 (62,63), SYT9 (64), CAMTA1 (65), GRIA4 (66), and IGF1R (67-70). Additionally, DMRs that 640 contributed to enrichment for heart-related gene ontology terms included TNN/3, a cardiac-641 specific gene that codes for cardiac troponin I, whose absence leads to severe pediatric 642 cardiomyopathy (71), and GATA4, which encodes a member of the GATA family of zinc finger 643 transcription factors, is essential for mammalian cardiac development, and whose sequence 644 variants have been identified in individuals with CHDs (72). Whether the differential 645 methylation in the genes we identified plays an etiologic role or reflects epigenomic effects 646 downstream of the development of CHDs remains to be determined.

647

648 While this is, to our knowledge, the largest DNA methylation study of CHDs in DS, our sample 649 size of 86 DS newborns may still have limited our ability to detect genome-wide significant (q 650 <0.05) DMRs. Additionally, only around half of DMRs in all comparisons were methylated in 651 the same direction in the discovery and replication groups, potentially due to the very small 652 sample sizes and absence of confounding variable data to use for correction in the replication 653 group, as well as high interindividual variation in methylation. The genes to which our DMRs 654 mapped did not heavily coincide with those identified in previous epigenetic studies of DS-655 CHD (73,74), likely because those studies included small numbers of DS subjects, used non-656 NDBS biospecimens assayed with array-based methods, which do not have good coverage 657 over the regions we detected using WGBS, and did not account for cell type heterogeneity. 658 One exception to this is that we identified a DMR in the Males Only comparison that mapped

to SHC3, a gene that was differentially expressed in DS individuals with an endocardial
 cushion CHD (73). The DS field would benefit from further studies into the etiology and
 biomarkers of phenotypes common in the DS population, including CHDs.

662

663 **5.** Conclusions

664 Overall, this study presents the largest investigation of epigenetic variation associated with 665 CHDs in individuals with DS. We identified sex-specific global and regional methylation 666 differences in DS-CHD vs DS non-CHD newborns. Specifically, in males we found that 667 newborns with DS-CHD were globally hypomethylated compared to DS newborns without 668 CHD, a finding that appeared to be driven by differences in nRBC proportions between the 669 two groups. At the regional level, the majority of CHD DMRs identified by sex stratification did 670 not overlap by genomic coordinates, suggesting sex differences in the molecular signature of 671 CHDs in DS. Gene ontology analysis of DMRs from both sexes revealed enrichment in 672 pathways related to the heart, and some DS-CHD DMRs were also differentially methylated 673 in DS vs TD samples. Our results provide insight into the development of CHDs in newborns 674 with DS, pointing to sex-specific differences that warrant further investigation, and suggest 675 that DNA methylation may serve as a useful biomarker for investigating the variability of 676 clinical features within the genetic disorder of DS.

677

678 679

680 **DECLARATIONS**

681 Ethics approval and consent to participate

This study was approved by Institutional Review Boards at the California Health and Human

683 Services Agency, University of Southern California, and University of California Davis.

684

685 **Consent for publication**

686	Deidentified NDBS were obtained from the California Biobank Program (SIS request number
687	572), with a waiver of consent from the Committee for the Protection of Human Subjects of
688	the State of California.
689	
690	Availability of data and materials
691	This study used biospecimens from the California Biobank Program. Any uploading of
692	genomic data (including genome-wide DNA methylation data) and/or sharing of these
693	biospecimens or individual data derived from these biospecimens has been determined to
694	violate the statutory scheme of the California Health and Safety Code Sections 124980(j),
695	124991(b), (g), (h), and 103850 (a) and (d), which protect the confidential nature of
696	biospecimens and individual data derived from biospecimens. Should we be contacted
697	regarding individual-level data contributing to the findings reported in this study, inquiries will
698	be directed to the California Department of Public Health Institutional Review Board to
699	establish an approved protocol to utilize the data, which cannot otherwise be shared peer-
700	to-peer.
701	
702	Code is available at
703	https://github.com/juliamouat/DownSyndrome_CongenitalHeartDefect_DNAmethylation
704	
705	Competing interests
706	The authors declare that they have no competing interests.
707	
708	Funding
709	This work was supported by National Institutes of Health NIEHS T32 ES007059 (JSM) and
710	P30 ES023513 (JML); an Alex's Lemonade Stand Foundation 'A' Award (AJD); Canadian

711		Institutes of Health Research (CIHR) postdoctoral fellowship MFE-146824 (BIL); CIHR
712		Banting postdoctoral fellowship BPF-162684 (BIL)
713		
714		Authors' contributions
715		BIL, AJD, and JML designed the study. AJD and JML supervised the project. AJD, PJL,
716		JPW, and JMS prepared data. SSM performed DNA extractions. SL performed array
717		analysis. JSM performed bioinformatic analyses. JSM, AJD, and JML interpreted results.
718		JSM drafted the manuscript and made figures and tables. PJL, AJD, and JML revised the
719		manuscript. All authors reviewed and approved the final manuscript.
720		
721		Acknowledgements
722		A subset of biospecimens and/or data used in this study were obtained from the California
723		Biobank Program at the California Department of Public Health (CDPH), SIS request
724		number 572, in accordance with Section 6555(b), 17 CCR. The CDPH is not responsible for
725		the results or conclusions drawn by the authors of this publication.
726		
727		We thank Robin Cooley and Steve Graham (Genetic Disease Screening Program, CDPH)
728		for their assistance and expertise in the procurement and management of NDBS
729		specimens. We thank the DNA Technologies and Expression Analysis Core at the UC Davis
730		Genome Center for library preparation and WGBS.
731 732		
733 734		REFERENCES
735 736	1.	Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, et al. Down syndrome. Nat Rev Dis Primers. 2020 Feb 6;6(1):9.
737 738 739	2.	Dobosz A, Bik-Multanowski M. Long-term Trends in the Prevalence of Congenital Heart Defects in Patients with Down Syndrome in Southern Poland. Dev Period Med. 2019 Oct 27;23(3):184–9.

- Irving CA, Chaudhari MP. Cardiovascular abnormalities in Down's syndrome: spectrum,
 management and survival over 22 years. Arch Dis Child. 2012 Apr;97(4):326–30.
- 4. Laursen HB. Congenital heart disease in Down's syndrome. Br Heart J. 1976 Jan;38(1):32–
 8.
- 5. Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJM, Gemke
 RJBJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a
 national study. J Pediatr. 2008 Jan;152(1):15–9.
- Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, et al. National
 population-based estimates for major birth defects, 2010–2014. Birth Defects Res. 2019 Nov
 1;111(18):1420–35.
- 750
 7. Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Dai L, et al. The genetic
 751 architecture of Down syndrome phenotypes revealed by high-resolution analysis of human
 752 segmental trisomies. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12031–6.
- Ackerman C, Locke AE, Feingold E, Reshey B, Espana K, Thusberg J, et al. An Excess of
 Deleterious Variants in VEGF-A Pathway Genes in Down-Syndrome-Associated
 Atrioventricular Septal Defects. Am J Hum Genet. 2012 Oct 5;91(4):646–59.
- Ramachandran D, Mulle JG, Locke AE, Bean LJH, Rosser TC, Bose P, et al. Contribution of
 Copy Number Variation to Down Syndrome-associated Atrioventricular Septal Defects.
 Genet Med. 2015 Jul;17(7):554–60.
- Ramachandran D, Zeng Z, Locke AE, Mulle JG, Bean LJH, Rosser TC, et al. Genome-Wide
 Association Study of Down Syndrome-Associated Atrioventricular Septal Defects. G3
 (Bethesda). 2015 Jul 20;5(10):1961–71.
- 11. Rambo-Martin BL, Mulle JG, Cutler DJ, Bean LJH, Rosser TC, Dooley KJ, et al. Analysis
 of Copy Number Variants on Chromosome 21 in Down Syndrome-Associated Congenital
 Heart Defects. G3 (Bethesda). 2017 Nov 15;8(1):105–11.
- 12. Sailani MR, Makrythanasis P, Valsesia A, Santoni FA, Deutsch S, Popadin K, et al. The
 complex SNP and CNV genetic architecture of the increased risk of congenital heart defects
 in Down syndrome. Genome Res. 2013 Sep;23(9):1410–21.
- Trevino CE, Holleman AM, Corbitt H, Maslen CL, Rosser TC, Cutler DJ, et al. Identifying
 genetic factors that contribute to the increased risk of congenital heart defects in infants with
 Down syndrome. Sci Rep. 2020 Oct 22;10(1):18051.
- 14. Cao J, Wu Q, Huang Y, Wang L, Su Z, Ye H. The role of DNA methylation in syndromic
 and non-syndromic congenital heart disease. Clinical Epigenetics. 2021 Apr 26;13(1):93.
- 15. Vecoli C, Pulignani S, Foffa I, Andreassi MG. Congenital Heart Disease: The Crossroads of
 Genetics, Epigenetics and Environment. Curr Genomics. 2014 Oct;15(5):390–9.

16. Laufer BI, Hwang H, Jianu JM, Mordaunt CE, Korf IF, Hertz-Picciotto I, et al. Low-Pass
Whole Genome Bisulfite Sequencing of Neonatal Dried Blood Spots Identifies a Role for
RUNX1 in Down Syndrome DNA Methylation Profiles. Hum Mol Genet. 2020 Oct 1;

- 17. Muskens IS, Li S, Jackson T, Elliot N, Hansen HM, Myint SS, et al. The genome-wide
 impact of trisomy 21 on DNA methylation and its implications for hematopoiesis. Nat
 Commun. 2021 Feb 5;12:821.
- 18. Croen LA, Shaw GM, Jensvold NG, Harris JA. Birth defects monitoring in California: a
 resource for epidemiological research. Paediatric and Perinatal Epidemiology.
 1991;5(4):423–7.
- 19. Laufer BI. FASTQ_Me [Internet]. 2020 [cited 2023 Feb 28]. Available from: https://github.com/ben-laufer/FASTQ_Me
- 20. Laufer BI. CpG_Me [Internet]. 2022 [cited 2022 Jan 20]. Available from: https://github.com/ben-laufer/CpG_Me
- 21. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for
 multiple tools and samples in a single report. Bioinformatics. 2016 Oct 1;32(19):3047–8.
- Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq
 applications. Bioinformatics. 2011 Jun 1;27(11):1571–2.
- 23. Laufer BI, Neier K, Valenzuela AE, Yasui DH, Schmidt RJ, Lein PJ, et al. Placenta and fetal
 brain share a neurodevelopmental disorder DNA methylation profile in a mouse model of
 prenatal PCB exposure. Cell Reports. 2022 Mar;38(9):110442.
- 795 24. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
 796 EMBnet.journal. 2011 May 2;17(1):10–2.
- 25. Xu Z, Xie C, Taylor JA, Niu L. ipDMR: identification of differentially methylated regions
 with interval P-values. Bioinformatics. 2020 Aug 17;37(5):711–3.
- 26. Koestler DC, Jones MJ, Usset J, Christensen BC, Butler RA, Kobor MS, et al. Improving
 cell mixture deconvolution by identifying optimal DNA methylation libraries (IDOL). BMC
 Bioinformatics. 2016 Mar 8;17:120.
- 27. Hansen KD, Langmead B, Irizarry RA. BSmooth: from whole genome bisulfite sequencing
 reads to differentially methylated regions. Genome Biology. 2012 Oct 3;13(10):R83.
- 804 28. Korthauer K, Chakraborty S, Benjamini Y, Irizarry RA. Detection and accurate false
 805 discovery rate control of differentially methylated regions from whole genome bisulfite
 806 sequencing. Biostatistics. 2019 Jul 1;20(3):367–83.
- 807 29. Haftorn KL, Denault WRP, Lee Y, Page CM, Romanowska J, Lyle R, et al. Nucleated red
 808 blood cells explain most of the association between DNA methylation and gestational age.
 809 Commun Biol. 2023 Feb 27;6(1):1–11.

- 810 30. Kursa MB, Rudnicki WR. Feature Selection with the Boruta Package. Journal of Statistical
 811 Software. 2010 Sep 16;36:1–13.
- 31. Das P, Roychowdhury A, Das S, Roychoudhury S, Tripathy S. sigFeature: Novel Significant
 Feature Selection Method for Classification of Gene Expression Data Using Support Vector
 Machine and t Statistic. Frontiers in Genetics [Internet]. 2020 [cited 2023 Feb 13];11.
 Available from: https://www.frontiersin.org/articles/10.3389/fgene.2020.00247
- 32. Lawrence M, Gentleman R, Carey V. rtracklayer: an R package for interfacing with genome
 browsers. Bioinformatics. 2009 Jul 15;25(14):1841–2.
- 33. Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, et al. Software for
 Computing and Annotating Genomic Ranges. PLOS Computational Biology. 2013 Aug
 8;9(8):e1003118.
- 34. Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable
 Venn and Euler diagrams in R. BMC Bioinformatics. 2011 Jan 26;12(1):35.
- 35. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene
 lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
- 36. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the
 comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009 Jan;37(1):1–
 13.
- 37. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves
 functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010 May;28(5):495–
 501.
- 38. de Goede OM, Lavoie PM, Robinson WP. Characterizing the hypomethylated DNA
 methylation profile of nucleated red blood cells from cord blood. Epigenomics. 2016
 Nov;8(11):1481–94.
- 39. Salas LA, Zhang Z, Koestler DC, Butler RA, Hansen HM, Molinaro AM, et al. Enhanced
 cell deconvolution of peripheral blood using DNA methylation for high-resolution immune
 profiling. Nat Commun. 2022 Feb 9;13(1):761.
- 40. Mordaunt CE, Jianu JM, Laufer B, Zhu Y, Dunaway KW, Bakulski KM, et al. Cord blood
 DNA methylome in newborns later diagnosed with autism spectrum disorder reflects early
 dysregulation of neurodevelopmental and X-linked genes [Internet]. Genomics; 2019 Nov
 [cited 2020 Apr 15]. Available from: http://biorxiv.org/lookup/doi/10.1101/850529
- 41. Nitzan I, Kasirer Y, Mimouni FB, Fink D, Wasserteil N, Hammerman C, et al. Elevated
 Nucleated Red Blood Cells in Neonates with Down Syndrome and Pulmonary Hypertension.
 J Pediatr. 2019 Oct;213:232–4.

- 42. Aali BS, Malekpour R, Sedig F, Safa A. Comparison of maternal and cord blood nucleated
 red blood cell count between pre-eclamptic and healthy women. J Obstet Gynaecol Res.
 2007 Jun;33(3):274–8.
- 847
 43. Baschat AA, Gungor S, Kush ML, Berg C, Gembruch U, Harman CR. Nucleated red blood
 848
 849 cell counts in the first week of life: a critical appraisal of relationships with perinatal
 849 outcome in preterm growth-restricted neonates. Am J Obstet Gynecol. 2007
 850 Sep;197(3):286.e1-8.
- 44. de Goede OM, Razzaghian HR, Price EM, Jones MJ, Kobor MS, Robinson WP, et al.
 Nucleated red blood cells impact DNA methylation and expression analyses of cord blood hematopoietic cells. Clinical Epigenetics. 2015 Sep 11;7(1):95.
- 45. Hermansen M. Nucleated red blood cells in the fetus and newborn. Arch Dis Child Fetal
 Neonatal Ed. 2001 May;84(3):F211–5.
- 46. Redline RW. Elevated circulating fetal nucleated red blood cells and placental pathology in term infants who develop cerebral palsy. Hum Pathol. 2008 Sep;39(9):1378–84.
- 47. Yeruchimovich M, Dollberg S, Green DW, Mimouni FB. Nucleated red blood cells in infants of smoking mothers. Obstet Gynecol. 1999 Mar;93(3):403–6.
- 48. Yeruchimovich M, Mimouni FB, Green DW, Dollberg S. Nucleated red blood cells in
 healthy infants of women with gestational diabetes. Obstet Gynecol. 2000 Jan;95(1):84–6.
- 49. Bedrick AD. Nucleated red blood cells and fetal hypoxia: a biologic marker whose 'timing' has come? J Perinatol. 2014 Feb;34(2):85–6.
- 50. Teramo KA, Widness JA. Increased Fetal Plasma and Amniotic Fluid Erythropoietin
 Concentrations: Markers of Intrauterine Hypoxia. Neonatology. 2009 Feb;95(2):105–16.
- S1. Zakharchenko L, EL-Khuffash A, Hurley T, Kelly L, Melo A, Padden M, et al. Infants with
 Down syndrome and congenital heart disease have altered peri-operative immune responses.
 Pediatr Res. 2022 Mar 29;1–8.
- 52. Morton PD, Korotcova L, Lewis BK, Bhuvanendran S, Ramachandra SD, Zurakowski D, et
 al. Abnormal neurogenesis and cortical growth in congenital heart disease. Sci Transl Med.
 2017 Jan 25;9(374):eaah7029.
- 53. Peyvandi S, Xu D, Wang Y, Hogan W, Moon-Grady A, Barkovich AJ, et al. Fetal Cerebral
 Oxygenation Is Impaired in Congenital Heart Disease and Shows Variable Response to
 Maternal Hyperoxia. Journal of the American Heart Association. 2021 Jan 5;10(1):e018777.
- 54. Zhang Z, Stolrow HG, Christensen BC, Salas LA. Down Syndrome Altered Cell
 Composition in Blood, Brain, and Buccal Swab Samples Profiled by DNA-MethylationBased Cell-Type Deconvolution. Cells. 2023 Jan;12(8):1168.

- 55. Krahn KN, Nagraj VP, McCulloch MA, Zimmet AM, Fairchild KD. Hypoxemia in infants
 with Trisomy 21 in the Neonatal Intensive Care Unit. J Perinatol. 2021 Jun;41(6):1448–53.
- 56. Horiuchi M, Kirihara Y, Fukuoka Y, Pontzer H. Sex differences in respiratory and
 circulatory cost during hypoxic walking: potential impact on oxygen saturation. Sci Rep.
 2019 Jul 2;9(1):9550.
- 57. Mayoral SR, Omar G, Penn AA. Sex Differences in a Hypoxia Model of Preterm Brain
 Damage. Pediatr Res. 2009 Sep;66(3):248–53.
- 58. Bohuslavová R, Kolář F, Kuthanová L, Neckář J, Tichopád A, Pavlinkova G. Gene
 expression profiling of sex differences in HIF1-dependent adaptive cardiac responses to
 chronic hypoxia. Journal of Applied Physiology. 2010 Oct;109(4):1195–202.
- 59. Zhu Y, Gomez JA, Laufer BI, Mordaunt CE, Mouat JS, Soto DC, et al. Placental methylome
 reveals a 22q13.33 brain regulatory gene locus associated with autism. Genome Biology.
 2022 Feb 16;23(1):46.
- 60. Ma Q, Xiong F, Zhang L. Gestational hypoxia and epigenetic programming of brain
 development disorders. Drug Discov Today. 2014 Dec;19(12):1883–96.
- 61. Liu L, Li Y, Chen Q. The Emerging Role of FUNDC1-Mediated Mitophagy in
 Cardiovascular Diseases. Frontiers in Physiology [Internet]. 2021 [cited 2023 Mar 2];12.
 Available from: https://www.frontiersin.org/articles/10.3389/fphys.2021.807654
- 62. Liu Y, Lu P, Wang Y, Morrow BE, Zhou B, Zheng D. Spatiotemporal Gene Coexpression
 and Regulation in Mouse Cardiomyocytes of Early Cardiac Morphogenesis. J Am Heart
 Assoc. 2019 Jul 19;8(15):e012941.
- 63. Tan WLW, Anene-Nzelu CG, Wong E, Lee CJM, Tan HS, Tang SJ, et al. Epigenomes of
 Human Hearts Reveal New Genetic Variants Relevant for Cardiac Disease and Phenotype.
 Circulation Research. 2020 Aug 28;127(6):761–77.
- 64. Xie HH, Li J, Li PQ, Zhang AA, Li Y, Wang YZ, et al. A genetic variant in a homocysteine
 metabolic gene that increases the risk of congenital cardiac septal defects in Han Chinese
 populations. IUBMB Life. 2017 Sep;69(9):700–5.
- 65. Song K, Backs J, McAnally J, Qi X, Gerard RD, Richardson JA, et al. The Transcriptional
 Coactivator CAMTA2 Stimulates Cardiac Growth by Opposing Class II Histone
 Deacetylases. Cell. 2006 May 5;125(3):453–66.
- 66. Izarzugaza JMG, Ellesøe SG, Doganli C, Ehlers NS, Dalgaard MD, Audain E, et al. Systems
 genetics analysis identifies calcium-signaling defects as novel cause of congenital heart
 disease. Genome Medicine. 2020 Aug 28;12(1):76.
- 67. Benbouchta Y, De Leeuw N, Amasdl S, Sbiti A, Smeets D, Sadki K, et al. 15q26 deletion in
 a patient with congenital heart defect, growth restriction and intellectual disability: case
 report and literature review. Italian Journal of Pediatrics. 2021 Sep 16;47(1):188.

68. González-Guerra JL, Castilla-Cortazar I, Aguirre GA, Muñoz Ú, Martín-Estal I, Ávila-914 915 Gallego E, et al. Partial IGF-1 deficiency is sufficient to reduce heart contractibility, 916 angiotensin II sensibility, and alter gene expression of structural and functional cardiac 917 proteins. PLOS ONE. 2017 Aug 14;12(8):e0181760. 918 69. Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, Cemerlang N, et al. Cardiac-specific 919 IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic 920 dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes. 2010 Jun;59(6):1512-921 20. 922 70. Ock S, Lee WS, Ahn J, Kim HM, Kang H, Kim HS, et al. Deletion of IGF-1 Receptors in 923 Cardiomyocytes Attenuates Cardiac Aging in Male Mice. Endocrinology. 2016 924 Jan;157(1):336-45. 925 71. Kühnisch J, Herbst C, Al-Wakeel-Marquard N, Dartsch J, Holtgrewe M, Baban A, et al. 926 Targeted panel sequencing in pediatric primary cardiomyopathy supports a critical role of 927 TNNI3. Clinical Genetics. 2019;96(6):549-59. 928 72. Tomita-Mitchell A, Maslen CL, Morris CD, Garg V, Goldmuntz E. GATA4 sequence 929 variants in patients with congenital heart disease. J Med Genet. 2007 Dec;44(12):779–83. 930 73. Dobosz A, Grabowska A, Bik-Multanowski M. Hypermethylation of NRG1 gene correlates 931 with the presence of heart defects in Down's syndrome. J Genet. 2019 Dec;98:110. 932 74. Serra-Juhé C, Cuscó I, Homs A, Flores R, Torán N, Pérez-Jurado LA. DNA methylation 933 abnormalities in congenital heart disease. Epigenetics. 2015 Jan 14;10(2):167-77. 934